健康需求持续进阶，慢病管理的下一个价值增长点在何处？ 年度盘点国际药企的慢病管理进阶之路

Core Viewpoint - The increasing prevalence of chronic diseases in China, driven by an aging population and changing lifestyles, has led to a situation where chronic diseases are now a "normal part of life," creating significant health and economic burdens [1][2]. Group 1: Current Challenges in Chronic Disease Management - Chronic disease prevention and control in China faces a "high incidence, high mortality, high economic burden" and "low screening, low treatment, low compliance" dilemma, with 91% of total deaths attributed to chronic non-communicable diseases such as cardiovascular diseases, diabetes, and respiratory diseases [1]. - There is a growing demand for comprehensive management of chronic diseases, as patients experience co-morbidities and require integrated treatment approaches, yet investment in chronic disease management has decreased in recent years [2][3]. Group 2: Innovations in Treatment Approaches - AstraZeneca is focusing on breaking through the bottlenecks of single-point treatments by adopting a holistic view to address the interconnections between diseases, aiming to improve patient outcomes through innovative therapies and systematic treatment plans [4]. - The company has presented over 80 studies at major international conferences, covering cardiovascular, renal, metabolic, respiratory, and autoimmune treatment areas, providing new targets and ideas for clinical treatment [4]. Group 3: Future Directions and Strategic Initiatives - AstraZeneca plans to expand its product pipeline with over 40 new products and indications in chronic disease treatment, including areas such as amyloidosis, weight management, liver diseases, and systemic lupus erythematosus, creating a robust and diverse treatment matrix [8]. - The company is also enhancing grassroots diagnostic capabilities and leveraging technology, such as AR-assisted lung function testing, to improve screening rates and treatment efficiency for chronic respiratory diseases [10]. Group 4: Collaborative Models for Chronic Disease Management - The establishment of a graded diagnosis and treatment system is extending chronic disease management from hospitals to communities and homes, aiming for comprehensive coverage and improved management efficiency [9]. - AstraZeneca is promoting collaborative models, such as the "hospital-community linkage" approach, to provide standardized, integrated, and continuous chronic disease management services across various healthcare settings [9][10].